Gilead Sciences as a Stable, High Free Cash Flow Biotech

about 1 month ago

Chris Marutch

"Right, so now we're going into the biotech area. Gilead Sciences is not your typical speculative biotech; it's one of the blue chip names and a cash flow machine, boasting the highest free cash flow yield among the three at around 6.19%. Anchored by proven drugs for HIV and hepatitis C along with a growing oncology portfolio, the company generated $7.7 billion in its most recent quarter. With several phase three candidates that could lead to new commercial drugs in the next year or so, this is a stock for investors looking to accumulate stable, rewarding cash flow over time."

The speaker presents Gilead Sciences as a stable biotech investment with robust free cash flow and a solid portfolio of proven drugs. Despite the inherent risks in biotech, its diversified product base and near-term catalysts from phase three trials make it a favorable accumulation candidate for long-term investors.

Related Stocks